Bayer (FRA:BAYN) has been assigned a €131.00 ($155.95) target price by investment analysts at Sanford C. Bernstein in a research report issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price target suggests a potential upside of 25.86% from the company’s current price.

A number of other research firms also recently weighed in on BAYN. Citigroup set a €130.00 ($154.76) target price on Bayer and gave the stock a “buy” rating in a report on Thursday, October 5th. UBS Group set a €125.00 ($148.81) target price on Bayer and gave the stock a “buy” rating in a report on Monday, November 6th. Deutsche Bank set a €124.00 ($147.62) target price on Bayer and gave the stock a “buy” rating in a report on Friday, October 27th. Baader Bank set a €140.00 ($166.67) target price on Bayer and gave the stock a “buy” rating in a report on Wednesday, September 20th. Finally, Commerzbank set a €124.00 ($147.62) target price on Bayer and gave the stock a “buy” rating in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of €122.33 ($145.63).

Shares of Bayer (FRA BAYN) opened at €104.08 ($123.90) on Thursday. Bayer has a twelve month low of €99.69 ($118.68) and a twelve month high of €123.82 ($147.40). The firm has a market capitalization of $85,820.00 and a price-to-earnings ratio of 27.90.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/bayer-bayn-pt-set-at-131-00-by-sanford-c-bernstein.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.